Unlike gastrointestinal stromal tumors (GISTs), which benefit from molecular characterization and targeted therapies, LMS lacks KIT and DOG1 expression and typically follows a more aggressive course with limited systemic treatment options [4, 5]. This evidence concerns the gene ANO1 and gastrointestinal stromal tumor.